COMMITMENTS AND CONTINGENCIES (Tables)

9 Months Ended

Sep. 30, 2021

Commitments and Contingencies Disclosure [Abstract]

Schedule of Contingent Consideration

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the nine months ended September 30, 2021 and September 30, 2020 is as follows (in thousands):

Nine Months Ended September 30, 2021	Contingent Consideration Liability Related to Acquisition of:
	Arkis				Location in Financial Statements	Derma Sciences		ACell Inc.  (See Note 2)		Location in Financial Statements
	Short-term		Long-term			Long-term		Long-term
Balance as of January 1, 2021	$	3,415	$	11,746		$	230	$	—
Additions from acquisition of ACell	—		—			—		23,900
Transfers	(3,415)		3,415			—		—
Change in fair value of contingent consideration liabilities	—		$	(544)	Research and development	—		(900)		Selling, general and administrative
Balance as of September 30, 2021	$	—	$	14,617		$	230	$	23,000

Nine Months Ended September 30, 2020	Contingent Consideration Liability Related to Acquisition of:
	Arkis		Derma Sciences		Location in Financial Statements
	Long-term		Long-term
Balance as of January 1, 2020	$	14,210	$	230
Change in fair value of contingent consideration liabilities	(45)		—		Research and development
Balance as of September 30, 2020	$	14,165	$	230